Recent landmark studies in melanoma, cutaneous squamous cell carcinoma (cSCC), head and neck cancer (HNC) and sarcoma have established neoadjuvant immune therapy as a potential standard of care for patients with locally advanced cancers.
This session provides an overview about palliative radiation for head and neck and skin malignancies. It focuses on a brief review of the available evidence supporting palliative radiation therapy for these diseases and help participants identify resources to help guide them in application.
This presentation reviews the role of radiation therapy in the management of non-spine bone metastases, focusing on patient evaluation, treatment intent, dose selection, and integration with systemic and surgical care.
This presentation focuses on the management of spine metastases with palliative radiation, emphasizing a multidisciplinary and patient-centered approach incorporating up-to-date clinical practice guidelines and evidence.
The management of locally advanced lung cancer increasingly relies on multidisciplinary collaboration. Advances in neoadjuvant and perioperative chemoimmunotherapy have significantly improved outcomes for patients with resectable non-small cell lung cancer.
This combined immunotherapy track and lung cancer track brings together leading experts to discuss recent, cutting-edge trials and strategies in treating both locally advanced and metastatic non-small cell lung cancer (NSCLC). Dr.
This activity discusses some of the newer treatment techniques, including stereotactic body radiation (SBRT), adaptive radiation therapy and protons being utilized in gynecologic cancer.
The Michigan Radiation Oncology Quality Consortium (MROQC) is a Blue Cross Blue Shield of Michigan-Blue Care Network (BCBSM-BCN) sponsored Collaborative Quality Initiative (CQI).
Molecular testing is an integral component of multidisciplinary management of breast cancer. Recent evidence underscores the importance of molecular assays in radiation therapy decision making.
Facebook
X
LinkedIn
Forward
